Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness

This resource was selected by SMI Adviser content partners and approved by the SMI Adviser clinical expert team for inclusion in the knowledge base.

In Canada, atypical long-acting injectable (LAI) antipsychotics available for the treatment of schizophrenia or bipolar disorder include the following: risperidone, aripiprazole, paliperidone palmitate, and paliperidone extended-release. The purpose of this report is to evaluate the clinical effectiveness and cost-effectiveness, for the use of atypical injectable antipsychotics for patients with schizophrenia or bipolar disorder.

ACCESS RESOURCE

  • Was this Helpful ?
  • YesNo

Join our #MissionForBetter now

Sign up for our newsletter. We’ll let you know about new resources, education, and more.

Saved Posts

X